French-based data science team develops AI tool for predicting cancer drug approval following phase I trials | 2019-12-16


PARIS – A crew of medical researchers and engineers from the Gustave Roussy Institute, in Villejuif, France, and Paris-Sud College just lately developed a synthetic intelligence system referred to as Resolved2, designed to evaluate potential most cancers medication. As Loïc Verlingue, lead most cancers specialist on the info science crew on the Gustave Roussy Institute, defined to BioWorld MedTech, “this AI is meant to foretell effectively whether or not a most cancers remedy molecule will obtain authorization or not inside six years of pharmacological knowledge and part I medical trials.”

Synthetic intelligence BioWorld MedTech Europe Most cancers Digital well being

Already a subscriber? Register 

Source link

Leave a Reply

Your email address will not be published.

Previous Post

Big Data Analytics In Healthcare Market Is Thriving Continuously By Top Key Players like Allscripts Healthcare Solutions, Cerner Corporation, Dell Emc, Epic System Corporation, Ge Healthcare, IBM, Microsoft, Optum

Next Post

e.l.f.’s “Eyes. Lips. Face.” Music Video Breaks “The Rules Of Beauty” — Here’s Why

Related Posts